By interaction with FMR1, LOXL2 may modify the mRNA translation of genes implicated in the hallmarks of cancer, such as TP53, VEGF, hTERT, TGFB2, and other essential oncogenes [85]. This evidence concerns the gene TGFB2 and cancer.